RudaCure: Targeting diseases with high 未满足的需求 to improve quality of life
RudaCure CEO Yongho Kim spent 15 years conducting basic biomedical research on pain and 感觉障碍 at university while mentoring the next generation of researchers. Frustrated by the lack of commercialized technologies that could help patients, he founded his own 生物科技公司 and is now developing treatments covering the full spectrum of intractable 感觉障碍 with high 未满足的需求 — from 干眼症 to pain. [Related article: Developing treatments for '感觉障碍' related to quality of life, from 干眼症 to pain]
Currently, the 干眼症治疗药 candidate RCI001 is progressing at the fastest pace, with plans to advance to Phase 1 临床试验 domestically and internationally next year. In addition, the 疼痛治疗药 RCI002, 特应性皮炎 treatment RCI003, metastatic cancer treatment RCI004, and AMD/age-related 黄斑变性 treatment RCI005 are also under development.
← 返回列表Company
K-Bio风投企业追求全球新药开发——2021年值得关注的企业及差异化优势
2021-12-30